{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:45:40Z","timestamp":1785703540311,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.trim.2026.102413","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:14:46Z","timestamp":1782573286000},"page":"102413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcomes of myeloablative allogeneic peripheral blood stem cell transplantation for relapsed\/refractory T-ALL\/LBL: A single-center study"],"prefix":"10.1016","volume":"97","author":[{"given":"Xiaofan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.trim.2026.102413_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of T cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.trim.2026.102413_bb0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2026.102413_bb0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"issue":"10230","key":"10.1016\/j.trim.2026.102413_bb0020","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.trim.2026.102413_bb0025","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/annonc\/mdt221","article-title":"Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude children\u2019s research hospital from 1962 to 2002","volume":"24","author":"Sandlund","year":"2013","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.trim.2026.102413_bb0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12032-015-0551-9","article-title":"Outcomes of dose-adjusted Berlin-Frankfurt-M\u00fcnster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma","volume":"32","author":"Xie","year":"2015","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.trim.2026.102413_bb0035","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","article-title":"Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.trim.2026.102413_bb0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2015.61.5385","article-title":"Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study","volume":"34","author":"Lepretre","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.trim.2026.102413_bb0045","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.trim.2026.102413_bb0050","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.trim.2026.102413_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","article-title":"T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies","volume":"32","author":"Vadillo","year":"2018","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.trim.2026.102413_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"26","key":"10.1016\/j.trim.2026.102413_bb0065","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from children\u2019s oncology group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.trim.2026.102413_bb0070","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.trim.2026.102413_bb0075","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.6004\/jnccn.2017.0147","article-title":"NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017","volume":"15","author":"Brown","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"3","key":"10.1016\/j.trim.2026.102413_bb0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"14","key":"10.1016\/j.trim.2026.102413_bb0085","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.2023022920","article-title":"Classification and risk stratification in T-lineage acute lymphoblastic leukemia","volume":"145","author":"P\u00f6l\u00f6nen","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2026.102413_bb0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrc2804","article-title":"Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer","volume":"10","author":"Jenq","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.trim.2026.102413_bb0095","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.trim.2026.102413_bb0100","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00277-023-05286-3","article-title":"Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia\/lymphoma","volume":"102","author":"Huang","year":"2023","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.trim.2026.102413_bb0105","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1158\/1078-0432.CCR-22-2924","article-title":"Single-cell transcriptomics reveals immune reconstitution in patients with R\/R T-ALL\/LBL treated with donor-derived CD7 CAR-T therapy","volume":"29","author":"Chen","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.trim.2026.102413_bb0110","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.trim.2026.102413_bb0115","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2026.102413_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2023.2264431","article-title":"Use of PD-1 blockade in refractory\/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports","volume":"65","author":"Rivera-Francia","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.trim.2026.102413_bb0125","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41409-021-01445-0","article-title":"Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma","volume":"56","author":"Inoue","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.trim.2026.102413_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221108890","article-title":"Total body irradiation-based conditioning regimen improved the survival of adult patients with T-cell lymphoblastic lymphoma after allogeneic peripheral blood stem cell transplantation","volume":"31","author":"Niu","year":"2022","journal-title":"Cell Transplant."},{"issue":"3","key":"10.1016\/j.trim.2026.102413_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jtct.2022.11.013","article-title":"Donor CD7 chimeric antigen receptor T cell bridging to allogeneic hematopoietic stem cell transplantation for T cell hematologic malignancy","volume":"29","author":"Li","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"11","key":"10.1016\/j.trim.2026.102413_bb0140","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000790","article-title":"Haploidentical versus matched sibling donor hematopoietic stem cell transplantation for adult patients with R\/R acute lymphoblastic leukemia: a study from the acute leukemia working Party of the European Society for blood and marrow transplantation","volume":"6","author":"Nagler","year":"2022","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.trim.2026.102413_bb0145","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41409-018-0401-4","article-title":"Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation","volume":"54","author":"Ustun","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"3\u20134","key":"10.1016\/j.trim.2026.102413_bb0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10428199809068567","article-title":"Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Helg","year":"1998","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.trim.2026.102413_bb0155","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:46:12Z","timestamp":1785699972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0966327426000717"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102413","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of myeloablative allogeneic peripheral blood stem cell transplantation for relapsed\/refractory T-ALL\/LBL: A single-center study","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102413"}}